Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 5 de 5
Filtrar
Mais filtros










Base de dados
Intervalo de ano de publicação
1.
Gynecol Obstet Invest ; 73(4): 321-5, 2012.
Artigo em Inglês | MEDLINE | ID: mdl-22487709

RESUMO

BACKGROUND/AIMS: To investigate the reproductive outcome after hysteroscopic resection of uterine septum in women with septate uterus and otherwise idiopathic primary infertility. METHODS: Sixty-eight patients with septate uterus and idiopathic primary infertility were included in this prospective observational study. All patients underwent hysteroscopic metroplasty with scissors under general anesthesia. Main outcome measures were clinical pregnancy rate, live birth and abortion rate at 12 months' follow-up and at mean follow-up time. RESULTS: At 12 months' follow-up, the clinical pregnancy rate, the live birth rate and the abortion rate were 44% (30/68), 36.8% (25/68) and 16.6% (5/30), respectively. At total follow-up time, the overall pregnancy rate, the live birth rate and the abortion rate were 53.8% (35/65), 41.5% and 14.2% (7/35), respectively, while the stillbirth rate was 2.8% (1/35). CONCLUSION: Hysteroscopic metroplasty in women with septate uterus and unexplained infertility could improve clinical pregnancy rate and live birth rate in patients with otherwise unexplained infertility. If such a patient is looking for a spontaneous pregnancy, this is more likely to occur during the first 15 months following the procedure.


Assuntos
Histeroscopia , Infertilidade Feminina/cirurgia , Resultado da Gravidez , Útero/anormalidades , Útero/cirurgia , Aborto Espontâneo/epidemiologia , Adulto , Feminino , Humanos , Infertilidade Feminina/etiologia , Nascido Vivo/epidemiologia , Gravidez , Resultado da Gravidez/epidemiologia , Natimorto/epidemiologia
3.
Fertil Steril ; 95(6): 2024-8, 2011 May.
Artigo em Inglês | MEDLINE | ID: mdl-21334613

RESUMO

OBJECTIVE: To assess whether the clinical pregnancy rate of patients treated with recombinant FSH and IUI can be improved by the addition of a GnRH antagonist. DESIGN: Prospective, controlled study. SETTING: Reproductive medicine clinic. PATIENT(S): Ninety-three patients with primary or secondary infertility. INTERVENTION(S): Patients were allocated to controlled ovarian stimulation with recombinant FSH (50-150 IU/d) only (control group, n=45) or to recombinant FSH (50-150 IU/d) plus ganirelix (0.25 mg/d, starting when the leading follicle was ≥16 mm; n=48). A single insemination was performed 36 hours after hCG was given (10,000 IU, IM) in both groups. Both groups were allowed at least three cycles. MAIN OUTCOME MEASURE(S): Clinical pregnancy rate, premature luteinization rate, and follicular development. RESULT(S): Clinical pregnancy rate (22% vs. 11%), cumulative pregnancy rate (52% vs. 31%), and number of mature follicles (2.1±1.08 vs. 1.4±0.95) were statistically significantly higher in the ganirelix group compared with the control group. The premature luteinization rate was significantly lower in the ganirelix group (1.7% vs. 17.5%). CONCLUSION(S): The use of a GnRH antagonist in conjunction with controlled ovarian stimulation and IUI significantly increases pregnancy rates and reduces the incidence of premature luteinization.


Assuntos
Hormônio Liberador de Gonadotropina/antagonistas & inibidores , Antagonistas de Hormônios/uso terapêutico , Infertilidade/terapia , Inseminação Artificial/métodos , Indução da Ovulação/métodos , Adulto , Características da Família , Feminino , Fármacos para a Fertilidade Feminina/administração & dosagem , Fármacos para a Fertilidade Feminina/uso terapêutico , Hormônio Foliculoestimulante/administração & dosagem , Hormônio Foliculoestimulante/uso terapêutico , Hormônio Liberador de Gonadotropina/administração & dosagem , Hormônio Liberador de Gonadotropina/análogos & derivados , Hormônio Liberador de Gonadotropina/uso terapêutico , Antagonistas de Hormônios/administração & dosagem , Humanos , Infertilidade/tratamento farmacológico , Masculino , Gravidez , Taxa de Gravidez , Proteínas Recombinantes/administração & dosagem , Proteínas Recombinantes/uso terapêutico , Útero
4.
Gynecol Endocrinol ; 27(8): 543-50, 2011 Aug.
Artigo em Inglês | MEDLINE | ID: mdl-20653338

RESUMO

AIM: Postpartum mood disturbances are common among Greek women, with postpartum depression (PPD) being as high as 19%. This study aimed to investigate whether sex steroid hormone levels affect the incidence of postpartum mood disturbances. MATERIALS AND METHODS: Fifty-seven women were evaluated for postpartum mood disturbances using the Postpartum Blues Questionnaire and the Edinburgh Postnatal Depression Scale on the 1st and 6th week. Serum estradiol, progesterone and testosterone concentrations were measured upon admission for delivery and daily until the fourth postpartum day. We then studied the association between hormone levels and the scores in the two psychometric scales. RESULTS: Testosterone was the only hormone that was marginally associated with psychometric scoring in simple regression analysis. (Postpartum Blues during days 1-4: b = 4.291, 95% C.I. -0.796 to 9.377 and p-value = 0.096). Women with lower testosterone drops had higher scores in Postpartum Blues Questionnaire. This association, however, lost statistical significance in the multivariable analysis after adjusting for pregnancy duration. In multiple regression analysis, only pregnancy duration had the most constant adverse effect on psychometric scores: The shorter the duration of pregnancy, the higher the scores for Postpartum Blues. (r = -0.39, p < 0.01). CONCLUSIONS: Our findings do not indicate an association between the occurrence of postpartum mood disorders and sex steroid hormone levels. Preterm labour may be associated with a higher risk of postpartum mood disturbances.


Assuntos
Depressão Pós-Parto/sangue , Estradiol/sangue , Transtornos do Humor/sangue , Progesterona/sangue , Transtornos Puerperais/sangue , Testosterona/sangue , Adulto , Depressão Pós-Parto/epidemiologia , Depressão Pós-Parto/etiologia , Feminino , Grécia/epidemiologia , Maternidades , Hospitais Universitários , Humanos , Incidência , Pessoa de Meia-Idade , Transtornos do Humor/epidemiologia , Transtornos do Humor/etiologia , Trabalho de Parto Prematuro/fisiopatologia , Trabalho de Parto Prematuro/psicologia , Período Periparto , Gravidez , Escalas de Graduação Psiquiátrica , Transtornos Puerperais/epidemiologia , Transtornos Puerperais/etiologia , Fatores de Risco , Adulto Jovem
5.
Gynecol Endocrinol ; 24(4): 220-3, 2008 Apr.
Artigo em Inglês | MEDLINE | ID: mdl-18382909

RESUMO

The aim of the present study was to evaluate the biochemical and clinical effects of the combined pill consisting of ethinyl estradiol (EE) and drospirenone (DRSP) in hirsute patients. Fifty-two adolescents or young women from Greece were treated with 30 mug EE and 3 mg DRSP for 1 year. Hirsutism was evaluated by the Ferriman-Gallway (FG) score in the initial visit and at 3, 6 and 12 months. Follicle-stimulating hormone, luteinizing hormone, etradiol, free and total testosterone (T), sex hormone-binding globulin (SHBG), androstenedione and dehydroepiandrosterone sulfate were determined at the same intervals. Hirsutism improved and FG scores reduced to 77.4%, 67.2% and 51.8% at 3, 6 and 12 months, respectively. Plasma SHBG levels rose, while free and total T levels reduced from the third month onwards. In conclusion, the EE/DRSP pill improves hirsutism in women via antiandrogenic and antimineralocorticoid action. The biochemical manifestations of hyperandrogenism are also improved.


Assuntos
Androstenos/administração & dosagem , Hirsutismo/tratamento farmacológico , Administração Oral , Adolescente , Adulto , Combinação de Medicamentos , Etinilestradiol/administração & dosagem , Feminino , Hormônio Foliculoestimulante/sangue , Seguimentos , Grécia , Hirsutismo/sangue , Hirsutismo/complicações , Humanos , Hormônio Luteinizante/sangue , Antagonistas de Receptores de Mineralocorticoides/administração & dosagem , Síndrome do Ovário Policístico/sangue , Síndrome do Ovário Policístico/complicações , Globulina de Ligação a Hormônio Sexual/análise , Testosterona/sangue
SELEÇÃO DE REFERÊNCIAS
DETALHE DA PESQUISA
...